Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

详细信息    查看全文

• 作者：Antoinette G. Nelson¹ ; ^{antgnelson@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Xiaoping Zhang¹ ; ^{xzhang@rci.rutgers.edu" class="auth_mail" title="E-mail the corresponding author} ; Usha Ganapathi ^{ganapaus@rci.rutgers.edu" class="auth_mail" title="E-mail the corresponding author} ; Zoltan Szekely ^{zoltan@rci.rutgers.edu" class="auth_mail" title="E-mail the corresponding author} ; Charles W. Flexner² ; ^{flex@jhmi.edu" class="auth_mail" title="E-mail the corresponding author} ; Andrew Owen³ ; ^{aowen@liverpool.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; Patrick J. Sinko ; ^{sinko@rutgers.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：HIV/AIDS ; Antiretroviral drugs (ARV) ; Nanomedicine ; Nanotechnology ; Pre-exposure prophylaxis (PrEP) ; Drug delivery targeting ; Long-acting/extended-release (LA/ER)
• 刊名：Journal of Controlled Release
• 出版年：2015
• 出版时间：10 December 2015
• 年：2015
• 卷：219
• 期：Complete
• 页码：669-680
• 全文大小：701 K

文摘

The year 2016 will mark an important milestone — the 35th anniversary of the first reported cases of HIV/AIDS. Antiretroviral Therapy (ART) including Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of the greatest achievements in therapeutic drug research having transformed HIV infection into a chronically managed disease. Unfortunately, the lack of widespread preventive measures and the inability to eradicate HIV from infected cells highlight the significant challenges remaining today. Moving forward there are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new HIV infections from occurring, (2) to facilitate a functional cure, i.e., when HIV is present but the body controls it without drugs and (3) to eradicate established infection. Pre-exposure Prophylaxis (PrEP) represents a significant step forward in preventing the establishment of chronic HIV infection. However, the ultimate success of PrEP will depend on achieving sustained antiretroviral (ARV) tissue concentrations and will require strict patient adherence to the regimen. While first generation long acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise, significant DD treatment and prevention challenges persist. First, there is a critical need to improve cell specificity through targeting in order to selectively achieve efficacious drug concentrations in HIV reservoir sites to control/eradicate HIV as well as mitigate systemic side effects. In addition, approaches for reducing cellular efflux and metabolism of ARV drugs to prolong effective concentrations in target cells need to be developed. Finally, given the current understanding of HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and lymph nodes. The current review focuses on the DDS technologies, critical challenges, opportunities, strategies, and approaches by which novel delivery systems will help iterate towards prevention, functional cure and eventually the eradication of HIV infection.